(VIANEWS) – The Market ended the session with GENTIAN DIAGNOSTIC (GENT.OL) rising 17.78% to kr53.00 on Friday while Oslo Børs Benchmark Index_GI jumped 0.46% to kr1,422.35.
GENTIAN DIAGNOSTIC’s last close was kr45.00, 6.25% below its 52-week high of kr48.00.
About GENTIAN DIAGNOSTIC
Gentian Diagnostics ASA researches, develops, and produces biochemical reagents for use in medical diagnostics and research worldwide. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric immunoassay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a glomerular filtration rate marker for the diagnosis and therapeutic control of renal function; Gentian Retinol-Binding Protein Immunoassay for detection of retinol-binding protein in human serum and plasma; and canine CRP immunoassay test kit, a particle-enhanced turbidimetric immunoassay for quantitative determination of canine C-reactive protein in dog plasma and serum. It also provides SARS-CoV-2 total antibody immunoassay, quantitative antibody test captures the full immune response detecting antibodies targeting the S1-subunit. In addition, the company develops NT-proBNP Immunoassay, an aid in the diagnosis, monitoring and assessment of severity in individuals suspected of having congestive heart failure which is in product development phase. Further, it offers faecal calprotectin immunoassay, provides results of calprotectin in stool supporting diagnosis of inflammatory bowel disease; and faecal pancreatic elastase immunoassay which allows analysis of pancreatic elastase in stool to aid in diagnosis of pancreatic exocrine insufficiency. The company was founded in 2001 and is headquartered in Moss, Norway.
Earnings Per Share
As for profitability, GENTIAN DIAGNOSTIC has a trailing twelve months EPS of kr-0.38.
Return on Equity
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -3.82%.
Moving Average
GENTIAN DIAGNOSTIC’s worth is way above its 50-day moving average of kr39.98 and way above its 200-day moving average of kr40.40.
Volatility
GENTIAN DIAGNOSTIC’s last week, last month’s, and last quarter’s current intraday variation average was 1.76%, 0.44%, and 2.24%.
GENTIAN DIAGNOSTIC’s highest amplitude of average volatility was 2.45% (last week), 2.19% (last month), and 2.24% (last quarter).
Sales Growth
GENTIAN DIAGNOSTIC’s sales growth for the current quarter is 22.2%.
Yearly Top and Bottom Value
GENTIAN DIAGNOSTIC’s stock is valued at kr53.00 at 22:30 EST, way higher than its 52-week high of kr48.00.
More news about GENTIAN DIAGNOSTIC (GENT.OL).
